UBS Maintains Buy on Celldex Therapeutics, Raises Price Target to $45
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst David Dai maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $38 to $45.
UBS analyst David Dai maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $38 to $45.